Hollsteen
← Veeva

Research and development

Flow – sum over the period · $M

QuartersFiscal years

$MResearch and development · Q1 FY2016: $13.0M · 10-Q 0001564590-15-004860 filed Jun 4, 2015Research and development · Q2 FY2016: $15.0M · 10-Q 0001564590-15-007757 filed Sep 4, 2015Research and development · Q3 FY2016: $18.0M · 10-Q 0001564590-15-011387 filed Dec 10, 2015Research and development · Q4 FY2016: $20.0M · derived · 10-K 0001564590-17-005637 filed Mar 30, 2017Research and development · Q1 FY2017: $22.0M · 10-Q 0001564590-16-020379 filed Jun 8, 2016Research and development · Q2 FY2017: $24.0M · 10-Q 0001564590-16-025058 filed Sep 8, 2016Research and development · Q3 FY2017: $25.0M · 10-Q 0001564590-16-030006 filed Dec 8, 2016Research and development · Q4 FY2017: $26.0M · derived · 10-K 0001564590-18-007164 filed Mar 30, 2018Research and development · Q1 FY2018: $28.0M · 10-Q 0001564590-17-012336 filed Jun 8, 2017Research and development · Q2 FY2018: $33.0M · 10-Q 0001564590-18-022767 filed Sep 6, 2018Research and development · Q3 FY2018: $34.0M · 10-Q 0001564590-18-030635 filed Dec 7, 2018Research and development · Q4 FY2018: $37.0M · derived · 10-K 0001564590-19-009853 filed Mar 28, 2019Research and development · Q1 FY2019: $37.0M · 10-Q 0001564590-18-015244 filed Jun 7, 2018Research and development · Q2 FY2019: $39.0M · 10-Q 0001564590-18-022767 filed Sep 6, 2018Research and development · Q3 FY2019: $40.0M · 10-Q 0001564590-18-030635 filed Dec 7, 2018Research and development · Q4 FY2019: $43.0M · derived · 10-K 0001628280-20-004385 filed Mar 30, 2020Research and development · Q1 FY2020: $45.0M · 10-Q 0001564590-19-021933 filed Jun 6, 2019Research and development · Q2 FY2020: $51.0M · 10-Q 0001628280-19-011445 filed Sep 5, 2019Research and development · Q3 FY2020: $53.0M · 10-Q 0001628280-19-014779 filed Dec 5, 2019Research and development · Q4 FY2020: $61.0M · derived · 10-K 0001393052-21-000015 filed Mar 30, 2021Research and development · Q1 FY2021: $62.0M · 10-Q 0001628280-20-008982 filed Jun 4, 2020Research and development · Q2 FY2021: $70.0M · 10-Q 0001628279-20-000207 filed Sep 8, 2020Research and development · Q3 FY2021: $80.0M · 10-Q 0001628280-20-017286 filed Dec 9, 2020Research and development · Q4 FY2021: $82.0M · derived · 10-K 0001393052-22-000017 filed Mar 30, 2022Research and development · Q1 FY2022: $83.0M · 10-Q 0001393052-21-000028 filed Jun 4, 2021Research and development · Q2 FY2022: $95.0M · 10-Q 0001393052-21-000034 filed Sep 3, 2021Research and development · Q3 FY2022: $99.0M · 10-Q 0001393052-21-000040 filed Dec 3, 2021Research and development · Q4 FY2022: $105M · derived · 10-K 0001393052-23-000025 filed Mar 30, 2023Research and development · Q1 FY2023: $113M · 10-Q 0001393052-22-000025 filed Jun 3, 2022Research and development · Q2 FY2023: $134M · 10-Q 0001393052-22-000036 filed Sep 2, 2022Research and development · Q3 FY2023: $130M · 10-Q 0001393052-22-000048 filed Dec 7, 2022Research and development · Q4 FY2023: $143M · derived · 10-K 0001393052-24-000013 filed Mar 25, 2024Research and development · Q1 FY2024: $147M · 10-Q 0001393052-23-000034 filed Jun 2, 2023Research and development · Q2 FY2024: $157M · 10-Q 0001393052-23-000051 filed Sep 1, 2023Research and development · Q3 FY2024: $161M · 10-Q 0001393052-23-000066 filed Dec 7, 2023Research and development · Q4 FY2024: $164M · derived · 10-K 0001393052-25-000022 filed Mar 24, 2025Research and development · Q1 FY2025: $163M · 10-Q 0001393052-24-000024 filed Jun 4, 2024Research and development · Q2 FY2025: $176M · 10-Q 0001393052-24-000062 filed Sep 4, 2024Research and development · Q3 FY2025: $172M · 10-Q 0001393052-24-000075 filed Dec 9, 2024Research and development · Q4 FY2025: $182M · derived · 10-K 0001393052-26-000014 filed Mar 20, 2026Research and development · Q1 FY2026: $184M · 10-Q 0001393052-25-000042 filed Jun 2, 2025Research and development · Q2 FY2026: $193M · 10-Q 0001393052-25-000067 filed Aug 29, 2025Research and development · Q3 FY2026: $192M · 10-Q 0001393052-25-000078 filed Nov 21, 2025Research and development · Q4 FY2026: $199M · derived · 10-K 0001393052-26-000014 filed Mar 20, 2026Research and development · Q1 FY2027: $208M · 10-Q 0001393052-26-000026 filed Jun 5, 2026Research and development · Q2 FY2027: $223M · 10-Q 0001393052-26-000036 filed Aug 27, 202622313Q1 FY2016Q2 FY2027Q4 FY2021
$MResearch and development · Q3 FY2025: $172M · 10-Q 0001393052-24-000075 filed Dec 9, 2024Research and development · Q4 FY2025: $182M · derived · 10-K 0001393052-26-000014 filed Mar 20, 2026Research and development · Q1 FY2026: $184M · 10-Q 0001393052-25-000042 filed Jun 2, 2025Research and development · Q2 FY2026: $193M · 10-Q 0001393052-25-000067 filed Aug 29, 2025Research and development · Q3 FY2026: $192M · 10-Q 0001393052-25-000078 filed Nov 21, 2025Research and development · Q4 FY2026: $199M · derived · 10-K 0001393052-26-000014 filed Mar 20, 2026Research and development · Q1 FY2027: $208M · 10-Q 0001393052-26-000026 filed Jun 5, 2026Research and development · Q2 FY2027: $223M · 10-Q 0001393052-26-000036 filed Aug 27, 2026223172Q3 FY2025Q2 FY2027Q3 FY2026
Q2 FY2027
223$M
All values (46)
PeriodValue ($M)Status
Q2 FY2027223reported
Q1 FY2027208reported
Q4 FY2026199derived
Q3 FY2026192reported
Q2 FY2026193reported
Q1 FY2026184reported
Q4 FY2025182derived
Q3 FY2025172reported
Q2 FY2025176reported
Q1 FY2025163reported
Q4 FY2024164derived
Q3 FY2024161reported
Q2 FY2024157reported
Q1 FY2024147reported
Q4 FY2023143derived
Q3 FY2023130reported
Q2 FY2023134reported
Q1 FY2023113reported
Q4 FY2022105derived
Q3 FY202299reported
Q2 FY202295reported
Q1 FY202283reported
Q4 FY202182derived
Q3 FY202180reported
Q2 FY202170reported
Q1 FY202162reported
Q4 FY202061derived
Q3 FY202053reported
Q2 FY202051reported
Q1 FY202045reported
Q4 FY201943derived
Q3 FY201940reported
Q2 FY201939reported
Q1 FY201937reported
Q4 FY201837derived
Q3 FY201834reported
Q2 FY201833reported
Q1 FY201828reported
Q4 FY201726derived
Q3 FY201725reported
Q2 FY201724reported
Q1 FY201722reported
Q4 FY201620derived
Q3 FY201618reported
Q2 FY201615reported
Q1 FY201613reported

CSV with all sources · Technical ID: rnd

More metrics for Veeva

Income statement

Per share

Balance sheet

Cash flow

Revenue by segment/product/region

Sources & calculation
Value
$223M
Period
Q2 FY2027, ended Jul 31, 2026 · quarterly value (3 months, not cumulative)
Source
10-Q, filed Aug 27, 2026 · 0001393052-26-000036
Location
us-gaap:ResearchAndDevelopmentExpense
Confidence
1. – directly from an XBRL fact in the filing (or calculated exactly from it)

Versions

v1$223MAug 27, 202610-Q 0001393052-26-000036reported · confidence 1. · current